A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors Meeting Abstract
| Authors: | Patel, M. R.; Fakih, M.; Olszanski, A. J.; Lockhart, A. C.; Drilon, A. E.; Fu, S.; Bazhenova, L.; Patel, R.; Oliver, J. W.; Multani, P. S.; Wang, D. |
| Abstract Title: | A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 132s |
| Language: | English |
| ACCESSION: | WOS:000404665403173 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.2574 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2574 -- Source: Wos |
